The Top 10 Pitfalls in Initiating Advanced Therapy in IBD

Target Audience

The educational design of this activity addresses the needs of gastroenterologists and specialist nurse practitioners and physician assistants who are involved in managing patients with moderate to severe inflammatory bowel disease (IBD).

Program Description

In the United States, more than 1.5 million people are living with IBD, a group of devastating diseases that impose substantial burdens not only on patients but on the health care system and society. Many challenges or “pitfalls” in the management of IBD are associated with the delay of optimized therapy—delays that hinder successful patient outcomes. This Top 10 program has been designed to provide learners with a concise and easily digestible form of the information they need to avoid 10 common pitfalls in the treatment of IBD. Topics that will be covered by our expert gastroenterologist, Dr. Bruce Sands, include updates to the armamentarium of advanced therapies and their optimal placement in treatment, the identification of patients who would benefit from such therapies, monitoring strategies that support timely modification of therapies, and social determinants of health and disparities that may impact prompt aggressive treatment of IBD.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Identify patients with IBD who are candidates for initiation of biologic or advanced therapy
2. Select first-line non–tumor necrosis factor (TNF) inhibitor therapy for patients with moderate to severe IBD that requires escalation to advanced therapies
3. Engage in shared decision-making in ulcerative colitis (UC) and Crohn’s disease (CD), considering patient preferences and barriers to health care access

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Bruce E. Sands, MD, MS: Consulting Fees: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Galapagos, Genentech, Gilead Sciences, GSK, Janssen, Eli Lilly & Company, Merck & Co., Pfizer, Takeda, Teva; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: AbbVie, Bristol Myers Squibb, Celltrion, Janssen, Eli Lilly & Company, Merck & Co., Pfizer, Takeda

The Integritas planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.